FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:771 September 10, 1998 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Treatment with the appetite-suppressant drugs fenfluramine and dexfenfluramine, alone or in combination with phentermine, has been associated with cardiac-valve abnormalities.^1,2,3 Five echocardiologic surveys reviewed by the Food and Drug Administration suggested that the prevalence of cardiac-valve abnormalities is 30 to 38 percent among patients who have taken these drugs² and led to the withdrawal of fenfluramine and dexfenfluramine from the U.S. market on September 15, 1997. Whether these lesions resolve, progress, or remain unchanged after discontinuation of the drugs is not yet known. We report the possibility of regression of multivalvular regurgitation associated with fenfluramine and phentermine . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Caccitolo, J. A., Connolly, H. M., Rubenson, D. S., Orszulak, T. A., Schaff, H. V. (2001). Operation for anorexigen-associated valvular heart disease. J. Thorac. Cardiovasc. Surg. 122: 656-664 [Abstract] [Full Text]  
• Glazer, G. (2001). Long-term Pharmacotherapy of Obesity 2000: A Review of Efficacy and Safety. Arch Intern Med 161: 1814-1824 [Abstract] [Full Text]  
• Klintschar, M., Schwaiger, P., Mannweiler, S., Regauer, S., Kleiber, M. (2001). Evidence of Fetal Microchimerism in Hashimoto's Thyroiditis. J. Clin. Endocrinol. Metab. 86: 2494-2498 [Abstract] [Full Text]  
• Weissman, N. J., Tighe, J. F. Jr., Gottdiener, J. S., Gwynne, J. T. (1999). Prevalence of valvular-regurgitation associated with dexfenfluramine three to five months after discontinuation of treatment. J Am Coll Cardiol 34: 2088-2095 [Abstract] [Full Text]  
• Prasad, A., Mehra, M., Park, M., Scott, R., Uber, P. A., McFadden, P. M. (1999). Cardiac allograft valvulopathy: a case of donor-anorexigen-induced valvular disease. Ann. Thorac. Surg. 68: 1840-1841 [Abstract] [Full Text]  
• Kaal, S. E. J., Van den Hoogen, F. H. J., De Jong, E. M. G. J., Viëtor, H. E. (1999). Systemic Sclerosis: New Insights in Autoimmunity. Exp. Biol. Med. 222: 1-8 [Abstract] [Full Text]  
• Williamson, D. F., Yanovski, S. Z., Myers, M. D., Moye, L. A., Annegers, J. F., Paoletti, C. F., Shapiro, S., Khan, M. A., St. Peter, J. V., Herzog, C. A., Jick, H., Weissman, N. J., Gottdiener, J. S., Gwynne, J. T., Devereux, R. B., Cannistra, L. B., Cannistra, A. J. (1999). Appetite-Suppressant Drugs and Valvular Heart Disease. NEJM 340: 476-480 [Full Text]